Malawi

Total population: 15,906,000
Income group: Low
Life expectancy at birth: Total: 59 Males: 58 Females: 60

Cancer Mortality Profile*

Males
- Oesophagus: 32.0%
- Bladder: 10.4%
- Breast: 8.0%
- Other: 41.6%
- Mouth and oropharynx: 3.4%

Females
- Oesophagus: 39.0%
- Breast: 7.0%
- Ovarian: 15.8%
- Bladder: 7.3%
- Other: 32.1%

Age-Standardized Cancer Mortality Trends*

Males
- Oesophagus
- Breast
- Bladder
- Mouth and oropharynx

Females
- Ovarian
- Breast
- Oesophagus

Cancer Incidence

Males
- Kaposi sarcoma: 1,810
- Oesophagus: 1,074
- Non-Hodgkin lymphoma: 695
- Prostate: 349
- Bladder: 309

Females
- Kaposi sarcoma: 3,684
- Oesophagus: 997
- Non-Hodgkin lymphoma: 895
- Breast: 762
- Bladder: 472

Adult Risk Factors

<table>
<thead>
<tr>
<th>Current tobacco smoking (2011)</th>
<th>22.5%</th>
<th>5.4%</th>
<th>13.9%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total alcohol per capita consumption, in litres of pure alcohol (2010)</td>
<td>4.5</td>
<td>0.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Physical inactivity (2010)</td>
<td>4.3%</td>
<td>8.0%</td>
<td>6.2%</td>
</tr>
<tr>
<td>Obesity (2014)</td>
<td>1.4%</td>
<td>7.3%</td>
<td>4.3%</td>
</tr>
<tr>
<td>Household solid fuel use (2012)</td>
<td>-</td>
<td>-</td>
<td>97.0%</td>
</tr>
</tbody>
</table>

### Cancer Plans, Monitoring and Surveillance

| Has an operational cancer policy/strategy/action plan | No |
| Has a cancer registry | Yes |

**Scope**

- Population-based

**Coverage**

- Subnational

**Last year of data**

- 2010

### Cancer Primary Prevention Policies

#### Tobacco control

| Has an operational policy, strategy or action plan to reduce the burden of tobacco use | No |

**Smoke-free legislation**

- Up to two public places completely smoke-free

**Tobacco dependence treatment**

- None

**Warning labels**

- No warnings or small warnings

**Bans on advertising, promotion and sponsorship**

- Complete absence of ban, or ban that does not cover national television, radio and print media

**Tobacco taxes**

- 26–50% of retail price is tax

#### Overweight and obesity prevention and control

| Has an operational policy, strategy or action plan for reducing overweight/obesity | No |

#### Physical inactivity prevention and control

| Has an operational policy, strategy or action plan to reduce physical inactivity and/or promote physical activity | No |

#### Harmful use of alcohol prevention and control

| Has an operational policy, strategy or action plan to reduce the harmful use of alcohol | No |

#### National immunization

| Human Papillomavirus vaccination schedule | 1st contact, +2 month, +4 months (subnational) |

| Hepatitis B vaccination schedule | . . . |

| Hepatitis B vaccination coverage, infants | 89% |

### Cancer Screening and Early Detection

#### Cervical cancer

| Cervical cytology (PAP) | Not generally available at the public primary health care level |

| Acetic acid visualization (VIA) | Generally available at the public primary health care level |

#### Breast cancer

| Breast palpation / clinical breast exam (CBE) | Not generally available at the public primary health care level |

| Mammogram | Not generally available at the public primary health care level |

#### Colorectal cancer

| Faecal occult blood test or faecal immunological test | Not generally available at the public primary health care level |

| Bowel cancer screening by exam or colonoscopy | Not generally available at the public primary health care level |

### Cancer Treatment and Palliative Care

| Radiotherapy | Not generally available in the public health system |

| Total high energy teletherapy units / million inhabitants | 0.0 |

| Number of radiotherapy centres | . . . |

| Number of radiation oncologists | . . . |

| Chemotherapy (medicines not specified) | Not generally available in the public health system |

| Oral morphine (formulation not specified) | Generally available in the public health system |

| Non-methadone morphine equivalent consumption per cancer death (mg) | . . . |

| Community/home care for people with advanced stage cancer and other NCDs | Generally available |

* No mortality data available. Figures are based on national incidence estimates and modelled survival.

---